Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 6/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853835 | 1.00 | CA1 (0.39) | CA1CA2CA7CA9USP8 | |
| SCHEMBL30632305 | 0.94 | CA1 (0.39) | CA1CA2CA7CA9USP8 | |
| SCHEMBL21795577 | 0.94 | CA1 (0.39) | CA1CA2CA7CA9USP8 | |
| SCHEMBL7050692 | 0.86 | EGFR (0.38) | CA1CA2CA7CA9USP8 | |
| SCHEMBL7044981 | 0.82 | EGFR (0.47) | CA1CA2CA7CA9USP7 | |
| SCHEMBL20042518 | 0.81 | EGFR (0.35) | EGFR | |
| SCHEMBL30395802 | 0.81 | EGFR (0.35) | EGFR | |
| SCHEMBL24397228 | 0.81 | TDP2 (0.40) | EGFRPARP1PARP10 | |
| SCHEMBL23515574 | 0.81 | EGFR (0.39) | EGFR | |
| SCHEMBL7048653 | 0.81 | KDM4E (0.41) | CA1CA2CA7CA9USP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300132-A2 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-04-09 | — | — | EP | claimed |
| CN-117903113-A | Method for efficiently separating monohalogen substituted cyano-indenone isomer | 南京欧纳壹有机光电有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3620458-B1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2023-07-05 | — | — | EP | disclosed |
| US-20210323974-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE INCLUDING SAME | LG CHEM, LTD. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20200251661-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-08-06 | — | — | US | disclosed |
| EP-3620458-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-03-11 | — | — | EP | disclosed |
| EP-1300132-A2 | Agent for dyeing keratinous fibres | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200251661-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | ODC1, OR10J3, CYP1A1 | CA1 1902/4885CA2 3698/4885CA7 2083/4885 |
| US-20210323974-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE INCLUDING SAME | ODC1, AOX1, CYP1A1 | CA1 2325/4885CA2 4272/4885CA7 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.